<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006222</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02358</org_study_id>
    <secondary_id>AMC-023</secondary_id>
    <secondary_id>CDR0000068142</secondary_id>
    <nct_id>NCT00006222</nct_id>
  </id_info>
  <brief_title>EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma</brief_title>
  <official_title>A Phase I Trial of EMD 121974 in Patients With HIV Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of EMD 121974 in treating patients who have&#xD;
      HIV-related Kaposi's sarcoma. EMD 121974 may stop the growth of Kaposi's sarcoma by stopping&#xD;
      blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and toxicity of EMD 121974 in patients with HIV related Kaposi's&#xD;
      sarcoma.&#xD;
&#xD;
      II. Determine the antiangiogenic activity of this drug in these patients. III. Determine the&#xD;
      antitumor activity of this drug in these patients. IV. Determine the effect of this drug on&#xD;
      CD4 and CD8 cell counts and percentages, and on HIV viral load in these patients.&#xD;
&#xD;
      V. Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in&#xD;
      the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD&#xD;
      121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      at which no more than 1 of 6 patients experiences dose limiting toxicities.&#xD;
&#xD;
      Patients are followed for at least 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-30 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">March 2001</completion_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilengitide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven Kaposi's sarcoma&#xD;
&#xD;
          -  Systemic chemotherapy not required&#xD;
&#xD;
          -  Minimum of 2 lesions amenable to biopsy&#xD;
&#xD;
          -  Measurable or evaluable disease HIV positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: Karnofsky 70-100%&#xD;
&#xD;
          -  Life expectancy: At least 3 months&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count at least 750/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
          -  PT/PTT normal Bilirubin normal (bilirubin no greater than 3.5 mg/dL if secondary to&#xD;
             indinavir therapy, provided direct bilirubin no greater than upper limit of normal&#xD;
             (ULN))&#xD;
&#xD;
          -  AST (SGOT) no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No prior ischemic coronary artery disease including prior myocardial infarction&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
&#xD;
          -  No concurrent active infection (nonsystemic infection, e.g., herpes simplex, oral&#xD;
             thrush, or warts, allowed)&#xD;
&#xD;
          -  No gastric or duodenal ulcer within past 6 weeks unless healed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 2 weeks since prior antineoplastic biologic therapy and recovered&#xD;
&#xD;
          -  At least 3 weeks since prior myeloid growth factor&#xD;
&#xD;
          -  Growth factors and transfusion allowed if dose requirement is stable for 4 weeks prior&#xD;
             to therapy&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (6 weeks since prior nitrosourea or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  Concurrent hydroxyurea as antiretroviral therapy allowed if dose stable for 4 weeks&#xD;
             prior to study&#xD;
&#xD;
          -  No concurrent systemic cytotoxic chemotherapy&#xD;
&#xD;
          -  Recovered from prior endocrine therapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since major surgery or 10 days since minor surgery and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior experimental therapy for Kaposi's sarcoma and recovered&#xD;
&#xD;
          -  At least 2 weeks since prior local therapy to any indicator lesion&#xD;
&#xD;
          -  No concurrent investigational drugs (except antiretroviral therapy)&#xD;
&#xD;
          -  At least 2 weeks since prior acute treatment for infection or other serious medical&#xD;
             illness&#xD;
&#xD;
          -  Antiretroviral therapy must be stable for 4 weeks prior to study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J. Klencke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2001</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>May 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2004</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

